These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30473779)

  • 1. Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study.
    Chitasombat MN; Watcharananan SP
    F1000Res; 2018; 7():1568. PubMed ID: 30473779
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK; Pouch SM; Kissling KT
    Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis.
    de Paula MI; Bae S; Shaffer AA; Garonzik-Wang J; Felipe CR; Cristelli MP; Waldram MM; Massie AB; Medina-Pestana J; Segev DL; Tedesco-Silva H
    Transplantation; 2020 Oct; 104(10):2139-2147. PubMed ID: 31978003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors.
    Busca A; Passera R; Pini M; Zallio F; Dellacasa C; Audisio E; Giaccone L; Maffini E; Costa C; Cavallo R; Bruno B
    Am J Hematol; 2015 Jun; 90(6):E117-21. PubMed ID: 25752810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
    Couzi L; Helou S; Bachelet T; Martin S; Moreau K; Morel D; Lafon ME; Garrigue I; Merville P
    Transplant Proc; 2012 Nov; 44(9):2809-13. PubMed ID: 23146529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
    Andrade-Sierra J; Heredia-Pimentel A; Rojas-Campos E; Ramírez Flores D; Cerrillos-Gutierrez JI; Miranda-Díaz AG; Evangelista-Carrillo LA; Martínez-Martínez P; Jalomo-Martínez B; Gonzalez-Espinoza E; Gómez-Navarro B; Medina-Pérez M; Nieves-Hernández JJ
    Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand.
    Chiasakul T; Townamchai N; Jutivorakool K; Chancharoenthana W; Thongprayoon C; Watanatorn S; Avihingsanon Y; Praditpornsilpa K; Srisawat N
    Transplant Proc; 2015 Oct; 47(8):2460-4. PubMed ID: 26518951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial.
    Páez-Vega A; Gutiérrez-Gutiérrez B; Agüera ML; Facundo C; Redondo-Pachón D; Suñer M; López-Oliva MO; Yuste JR; Montejo M; Galeano-Álvarez C; Ruiz-San Millan JC; Los-Arcos I; Hernández D; Fernández-Ruiz M; Muñoz P; Valle-Arroyo J; Cano A; Rodríguez-Benot A; Crespo M; Rodelo-Haad C; Lobo-Acosta MA; Garrido-Gracia JC; Vidal E; Guirado L; Cantisán S; Torre-Cisneros J;
    Clin Infect Dis; 2022 Mar; 74(5):757-765. PubMed ID: 34228099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of More Vulnerable Patients for Cytomegalovirus Infection in Renal Transplant Recipients With Antithymocyte Globulin Induction Therapy: An Analysis of Risk Factors and Cell-Mediated Immunity.
    Jun KW; Lim JH; Hwang JK; Park SC; Kim JI; Yun SS; Kim MH
    Transplant Proc; 2021 Sep; 53(7):2252-2260. PubMed ID: 34452738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: Combining the best of two options?
    Hellemans R; Wijtvliet V; Bergs K; Philipse E; Vleut R; Massart A; Couttenye MM; Matheeussen V; Abramowicz D
    Transpl Infect Dis; 2021 Apr; 23(2):e13467. PubMed ID: 32935909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
    Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
    Eriksson M; Jokinen JJ; Söderlund S; Hämmäinen P; Lommi J; Lemström K
    Transpl Infect Dis; 2018 Jun; 20(3):e12868. PubMed ID: 29512249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
    Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy.
    Ko EJ; Yu JH; Yang CW; Chung BH
    Korean J Intern Med; 2019 Mar; 34(2):375-382. PubMed ID: 29237252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
    Cristelli MP; Felipe CR; Prizmic PSS; de Azevedo VFD; Viana LA; Tavares MG; Wagner de Castro Lima Santos D; de Paula MI; Medina-Pestana JO; Tedesco-Silva Junior H
    Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient.
    Hemmersbach-Miller M; Alexander BD; Pieper CF; Schmader KE
    Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):455-463. PubMed ID: 31758441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.